| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Asad E Patanwala | |
| Nicole M Acquisto | |||
| Brian L Erstad | |||
| P2860 | cites work | Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests | Q45881452 |
| Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose | Q46125200 | ||
| Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate | Q46139632 | ||
| Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation | Q46405965 | ||
| Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. | Q46818855 | ||
| Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation | Q47266490 | ||
| Availability of information for dosing injectable medications in underweight or obese patients | Q48969476 | ||
| Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. | Q50732476 | ||
| Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. | Q51792687 | ||
| Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study | Q53167882 | ||
| Urgent reversal of warfarin with prothrombin complex concentrate. | Q53255644 | ||
| Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital | Q21195016 | ||
| AASLD position paper: the management of acute liver failure | Q28246028 | ||
| Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial | Q28285511 | ||
| Use of factor IX complex in warfarin-related intracranial hemorrhage | Q28375864 | ||
| Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy | Q30310461 | ||
| Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary | Q33330139 | ||
| Coagulopathy in liver diseases | Q33389863 | ||
| Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation | Q33647003 | ||
| Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy | Q33735132 | ||
| Thrombogenicity of prothrombin complex concentrates | Q33739978 | ||
| Replacement of coagulation factors in liver or multiple organ dysfunction | Q33739998 | ||
| Management of bleeding following major trauma: an updated European guideline | Q33919178 | ||
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| Remodeling the blood coagulation cascade | Q34294608 | ||
| Mechanisms of thrombus formation | Q34815800 | ||
| Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. | Q35688850 | ||
| Coagulopathy in the trauma patient | Q36314566 | ||
| Update on transfusion medicine | Q36920718 | ||
| Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature | Q36923137 | ||
| Prothrombin complex concentrates: a brief review | Q37185539 | ||
| Perioperative hemostatic management of patients treated with vitamin K antagonists | Q37306386 | ||
| Correction of coagulopathy in warfarin associated cerebral hemorrhage | Q37418713 | ||
| Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment | Q37554147 | ||
| Coagulopathy in critically ill patients: part 2-soluble clotting factors and hemostatic testing | Q37668852 | ||
| New insights into acute coagulopathy in trauma patients | Q37733473 | ||
| Factor Xa inhibitors: next-generation antithrombotic agents | Q37760921 | ||
| Resuscitation and coagulation in the severely injured trauma patient | Q37819627 | ||
| Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies | Q42046164 | ||
| Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model | Q43180952 | ||
| Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model | Q43227114 | ||
| Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model | Q43242257 | ||
| Emergency reversal of anticoagulation after intracerebral hemorrhage | Q43574102 | ||
| Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding | Q43885621 | ||
| Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients | Q43889363 | ||
| Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage | Q45729423 | ||
| P433 | issue | 7-8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prothrombin complex concentrate | Q2044524 |
| P304 | page(s) | 990-999 | |
| P577 | publication date | 2011-07-05 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Prothrombin complex concentrate for critical bleeding | |
| P478 | volume | 45 |
| Q38191128 | Coagulopathy after severe pediatric trauma |
| Q34485905 | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
| Q38197728 | Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal |
| Q37999699 | Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors |
| Q38232683 | Improving appropriateness of blood utilization through prospective review of requests for blood products: the role of pathology residents as consultants |
| Q55452572 | Is fast reversal and early surgery (within 24 h) in patients on warfarin medication with trochanteric hip fractures safe? A case-control study. |
| Q35457130 | Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage |
| Q38171412 | Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy |
| Q47883018 | Prothrombin complex concentrate reversal of warfarin in patients with hip fracture |
| Q38014751 | Prothrombin complex concentrates in emergency bleeding disorders |
| Q35481316 | Prothrombin complex concentrates utility for warfarin-associated hemorrhage. |
| Q44380447 | Rapid bedside coagulometry prior to urgent neurosurgical procedures in anticoagulated patients |
| Q38009420 | Reversal of drug-induced anticoagulation: old solutions and new problems |
| Q39022849 | Role of agents for reversing the effects of target-specific oral anticoagulants |
| Q33420178 | Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor |
| Q85370189 | Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation? |
| Q52331525 | Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding. |
Search more.